Acquired Drug Patent — Intangible Asset Capitalisation
Capitalizing the cost of a purchased drug patent following regulatory approval of the drug.
| Account Name | Type | Debit ($) | Credit ($) |
|---|---|---|---|
| Intangible Assets — Drug Patent / IP | Asset (+) | 400,000,000.00 | - |
| Cash / Deferred Consideration Payable | Liability/Asset (-) | - | 400,000,000.00 |
💡 Accountant's Note
An acquired (not internally developed) drug patent is capitalised as an intangible asset at cost. For an approved drug acquisition, the asset is amortized over the remaining patent life (typically up to 20 years from filing, less time elapsed). For pre-approval drug acquisitions, the payment is typically expensed as in-process R&D (IPR&D).
Practitioner & Systems Framework
💻 ERP Architecture
Acquired drug IP is recognised in the intangible assets module at cost. For a drug acquired post-approval, the useful life equals the remaining patent protection period (considering patent term extensions, data exclusivity). Amortisation uses the straight-line method beginning from the date of acquisition (the drug is already approved and generating revenue). The intangible is tested for impairment annually and whenever impairment indicators arise (clinical setback, new competitor launch, pricing pressure). For acquisitions of pre-commercial IP, the payment is expensed as IPR&D unless separate identifiable assets with alternative uses exist.
⚠️ Audit Flags
Auditors confirm the useful life determination — the shorter of the legal patent life and the economic useful life. Assess the impairment indicators at each year-end, particularly for drugs facing biosimilar or generic competition (patent cliff). Test the separation of acquired IP value from any goodwill in a business combination. For pre-approval acquisitions, confirm that IPR&D expense treatment is appropriate (no alternative use; technically feasible commercial development has not yet been demonstrated). Confirm patent term extension applications are tracked and factored into the useful life.
📄 Required Documentation
Patent certificate and filing date, patent term extension documentation, useful life calculation (remaining patent protection), amortisation schedule, impairment testing annual review, acquisition agreement (allocation of consideration to IP), business combination purchase price allocation report, and competitive landscape assessment.
Professional Excel Template
Get the automated version of this entry. Includes built-in IFRS checks, VAT calculators, and SAP-ready upload formats.
Expert Analysis by Qusai Ahmad
General Accountant Supervisor & IFRS Specialist
Specialized in SAP GUI automation and Middle Eastern tax compliance. Building digital tools for the next generation of finance leaders.